Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection

Summary

This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and radiological suspicion of SARS-CoV2, will be randomized into two treatment groups at a 1:1 ratio to receive a 5-day CQ diphosphate tablets or placebo (tablet without active ingredient produced with the same physical characteristics).

Timeline

Start

2020-04-08

Primary completion

2020-05-14

Completion

2020-06-08

Drugs

Indications